Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Medtronic
Mallinckrodt
Dow
Baxter

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

RIZATRIPTAN BENZOATE Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Rizatriptan Benzoate, and what generic alternatives are available?

Rizatriptan Benzoate is a drug marketed by Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Mylan Pharms Inc, Natco Pharma Ltd, Panacea Biotec Ltd, Sandoz, Unichem Labs Ltd, Alkem Labs Ltd, Celltrion, Eci Pharms Llc, Emcure Pharms Ltd, Glenmark Generics, Invagen Pharms, and Teva Pharms. and is included in twenty-five NDAs.

The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

Drug patent expirations by year for RIZATRIPTAN BENZOATE
Drug Prices for RIZATRIPTAN BENZOATE

See drug prices for RIZATRIPTAN BENZOATE

Drug Sales Revenue Trends for RIZATRIPTAN BENZOATE

See drug sales revenues for RIZATRIPTAN BENZOATE

Recent Clinical Trials for RIZATRIPTAN BENZOATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 3

See all RIZATRIPTAN BENZOATE clinical trials

Recent Litigation for RIZATRIPTAN BENZOATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Forest Laboratories LLC v. Sigmapharm Laboratories LLC2014-09-03
SCHERING CORPORATION v. SANDOZ INC.2008-04-03
Plaintiff(s) v. Defendant(s)2008-01-31

See all RIZATRIPTAN BENZOATE litigation

Synonyms for RIZATRIPTAN BENZOATE
145202-66-0
1H-Indole-3-ehtanamine,N,N-dimehtyl-5-(1H-1,2,4-triazol-1-ylmethyl)-,monobenzoate
1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, monobenzoate
2-(5-((1H-1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)-N,N-dimethylethan-1-amine benzoate
2-(5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-1H-INDOL-3-YL)-N,N-DIMETHYLETHANAMINE BENZOATE
202R660
3-(2-(Dimethylamino)ethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)indole monobenzoate
AB0011227
AB07521
AB2000157
ABP000203
AC-734
AC1L2U9K
ACT04340
AK163196
AKOS015855933
AN-15582
API0004087
AX8006648
BC208268
BCP02149
benzoic acid; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
benzoic acid; rizatriptan
benzoic acid;N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
BG0594
C15H19N5.C7H6O2
CCG-101039
CHEBI:8875
CHEMBL1201032
CPD000525252
CS-2147
D00675
DTXSID20162937
FT-0631171
HMS2051B16
HMS2093K08
HMS2235M18
HMS3369I15
HMS3393B16
HMS3655K09
HMS3715D08
HY-B0206
I01-0305
INT-0008
J-008071
J-524222
JPRXYLQNJJVCMZ-UHFFFAOYSA-N
KS-00000XKR
KS-1189
L 705,126
L 705126
L-705,126
L-705126
LS-173238
Maxalt
Maxalt-MLT
MK 0462
MK 462
MK-0462
MK-462
MK-462;Maxalt;Maxalt
MLS001424197
MolPort-003-850-198
N,N-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1H-indole-3-yl)ethylamine
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine benzoate
N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOLE-3-ETHANAMINE BENZOATE
NC00289
NSC-758919
NSC758919
Pharmakon1600-01505189
R0107
R0181
RHB-103
rizatrimptan benzoate
Rizatriptan (benzoate)
Rizatriptan benzoate (JAN/USAN)
Rizatriptan Benzoate (Maxalt)
Rizatriptan benzoate [USAN:USP]
Rizatriptan Benzoate [USAN]
Rizatriptan benzoate salt, >=98% (HPLC)
Rizatriptan benzoate, European Pharmacopoeia (EP) Reference Standard
Rizatriptan benzoate, United States Pharmacopeia (USP) Reference Standard
Rizatriptan Benzoate(Maxalt)/
Rizatriptan for system suitability, European Pharmacopoeia (EP) Reference Standard
rizatriptan, benzoate
Rizatriptan(RIZ)
rizatriptane benzoate
RL01822
S1607
SAM001246615
SCHEMBL41226
SMR000525252
SR-01000763588
SR-01000763588-3
ST24039483
SW197669-2
UNII-WR978S7QHH
WR978S7QHH
X-2040
Paragraph IV (Patent) Challenges for RIZATRIPTAN BENZOATE
Tradename Dosage Ingredient NDA Submissiondate
MAXALT-MLT TABLET, ORALLY DISINTEGRATING;ORAL rizatriptan benzoate 020865 2006-02-17
MAXALT TABLET;ORAL rizatriptan benzoate 020864 2004-09-02

US Patents and Regulatory Information for RIZATRIPTAN BENZOATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 201993-001 Dec 31, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Emcure Pharms Ltd RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 204090-002 Nov 26, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
Unichem Labs Ltd RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 207836-001 Mar 7, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sandoz RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 079230-001 Dec 31, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Dow
Boehringer Ingelheim
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.